We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS RESISTANT ANIMALS
THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME
MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY
BIOADHESIVE DRUG DELIVERY COMPOSITIONS
SYNTHESIS AND CHARACTERIZATION OF SECOND GENERATION BENZOFURANONE RING SUBSTITUTED NOSCAPINE ANALOGS
CARBOCYANINES FOR G-QUADRUPLEX DNA STABILIZATION AND TELOMERASE INHIBITION
CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA